Research ArticleCORONAVIRUS

A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

See allHide authors and affiliations

Science Translational Medicine  02 Sep 2020:
Vol. 12, Issue 559, eabc3103
DOI: 10.1126/scitranslmed.abc3103

Elucidating seroprevalence in COVID-19

Individuals infected with SARS-CoV-2 mount an antibody response that may vary depending on the severity of the disease. Grzelak et al. assessed the amounts of anti–SARS-CoV-2 antibodies in serum samples from 491 healthy individuals before the pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. The authors developed and compared the performance of four different serological assays measuring antibody amounts and their neutralizing activity. The assays enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in asymptomatic, mildly symptomatic, and severe cases of COVID-19.

This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

View Full Text

Stay Connected to Science Translational Medicine